- The European Medicines Agency's advisory group, CHMP, has adopted a positive opinion, recommending the marketing authorization of Dynavax Technologies' (NASDAQ:DVAX) HEPLISAV-B for the active immunization against hepatitis B virus infection (HBV) in adults 18 years of age and older.
- The European Commission is expected to make a final decision on the marketing application in Q1 2021. If approved, Dynavax would receive marketing authorization for HEPLISAV-B in all EU member states.
- https://seekingalpha.com/news/3643604-dynavax-rises-4-ema-backs-marketing-application-for-heplisav-b
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.